ELISpot and FluoroSpot Assay Market Combating Chronic and Infectious Diseases: The ELISpot and Fluorospot Assay Market

ELISpot and FluoroSpot Assay Market worth $512.39 Mn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global ELISpot and FluoroSpot Assay Market- (By Product (Assay Kits (Assay Kits by Technique(ELISpot Assay Kits, FluroSpot Assay Kits), Assay Kits by Utility (Diagnostic Kits, Research Kits), Assay Kits by Analyte

(T-cell-based kits, B-cell-based kits, Other analytic kits), Analyzers, Ancillary products), By Application (Diagnostic Applications (Infectious Diseases, Transplants), Research Applications (Vaccine Development, Clinical Trials, Cancer Research)), By End-User (Hospitals & Clinical Labs, Research Institutes, Biopharmaceutical Companies and CROs)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global ELISpot and FluoroSpot Assay Market is valued at US$ 276.18 Mn in 2022, and it is expected to reach US$ 512.39 Mn by 2031, with a CAGR of 7.2% during a forecast period of 2024-2031.

Request for free Sample Pages: https://www.insightaceanalytic.com/request-sample/2000

The ELISpot and Fluorospot Assay Market is experiencing significant growth fueled by several factors. A key driver is the rising need for these tests in diagnosing and managing chronic illnesses like cancer and autoimmune disorders.

ELISpot and Fluorospot assays play a valuable role in evaluating treatment efficacy by measuring immune response, tracking disease progression over time, and potentially aiding in early disease detection. However, it's important to note some limitations. For instance, the National Cancer Institute has advised against using ELISpot tests to assess immune responses to cancer antigens in treatment studies.

Furthermore, the fight against infectious diseases like HIV and tuberculosis is also driving demand for these assays. ELISpot and Fluorospot assays offer valuable capabilities in monitoring the immune system's reaction to infectious agents and identifying disease-specific biomarkers.

List of Prominent Players in the ELISpot and FluoroSpot Assay Market:

• Jackson ImmunoResearch Inc (US),
• Krishgen Biosystems. (India)
• NATIONAL ANALYTICAL CORPORATION (India),
• STEMCELL Technologies Inc. (Canada),
• SERVA Electrophoresis GmbH (Germany),
• IST Scitific LTD (England).

• Oxford Immunotec (UK)
• Cellular Technology Limited (US)
• Mabtech (Sweden)
• Becton Dickinson and Company (US)
• Abcam plc. (UK)
• Bio-Techne. (US)
• Mikrogen Diagnostik (Germany)
• Autoimmun Diagnostika GmbH (Germany)
• U-CyTech (Netherlands)
• Medix Biochemica (Finland)
• Merck KGaA (Germany)
• Bio-Sys GmbH (Germany)
• Anogen-Yes Biotech Laboratories Ltd (Canada)
• Abnova Corporation (Taiwan)
• Biorbyt Ltd (UK),
• Tokyo Chemical Industry Co., Ltd. (Japan),
• MP BIOMEDICALS. (US),
• BOC Sciences. (US),
• ZenBio, Inc (US)

Market Dynamics:
Drivers-
Manufacturers increasingly focus on acquiring or engaging in agreements and collaborations with regional/domestic businesses for product distribution and manufacturing to address the rising need for ELISpot and FluoroSpot assay diagnostics in emerging regions.

For example, Siemens Healthineers (Germany) and UNICEF (US) formed cooperation in February 2022 to help build vulnerable health systems in Sub-Saharan Africa by enhancing access to diagnosis and treatment.

Because of fewer stringent laws and data requirements than in North American and European markets, regulatory policies in the Asia Pacific are more adaptable and business friendly. Furthermore, rising competition in mature countries will force ELISpot and FluoroSpot test makers to redirect their focus to expanding markets in the Asia Pacific and Latin America.

Challenges:
The most extensively used technology for measuring cytokine co-expression cells is intracellular cytokine staining (ICS), followed by flow cytometry. This poses a challenge for FluoroSpot assays, which are still relatively new but serve the same goal. While FluoroSpot assays are more sensitive than ICS, the latter is more aggressive in terms of performance,

which is an important advantage because analyzers must detect fluorescent spots precisely. This is especially difficult due to the overlapping detection wavelengths of the various fluorescent dyes. Numerous market players are working on improving their detecting technology to address this issue. Mabtech AB, for example, introduced the IRIS analyzer, which is based on RawSpot technology for accurate spot detection.

Regional Trends:
Due to several factors, North America will likely dominate the ELISpot and FluoroSpot assay market over the anticipated years. For starters, the region is experiencing an increase in the prevalence of cancer and infectious illness diseases.

As per the American Cancer Society's Cancer Statistics 2022, there will be 1,918,030 fresh cancer cases in the United States in 2022, which includes breast cancer, leukaemia, and lymphoma. Furthermore, research published in March 2022 by the American Academy of Paediatrics revealed that over one Mn people in the United States have chronic hepatitis B infections, which can lead to chronic illnesses such as liver cancer.

This is predicted to enhance vaccination demand and drive the growth of the ELISPOT assay, which is extremely valuable in studying infectious diseases.

Curious about this latest version of the report? @ https://www.insightaceanalytic.com/enquiry-before-buying/2000

Recent Developments:
• In Mar 2023, The T-Cell Select reagent kit from Oxford Immunotec, which is designed for in vitro diagnostic (IVD) use by accredited laboratories using the T-SPOT.TB test workflow, has received approval from the U.S. Food and Drug Administration (FDA) for the use of two additional cell isolation tools.

• In Mar 2022, Medix Biochemica launched a new brand to show how its recent acquisitions have made its services more exciting and how committed it is to the in vitro diagnostics (IVD) business. Medix Biochemica became the best IVD raw materials seller because of how quickly it grew.

Segmentation of ELISpot and FluoroSpot Assay Market-
By Product-
• Assay Kits
o Assay Kits by Technique
 ELISpot Assay Kits
 FluroSpot Assay Kits
o Assay Kits by Utility
 Diagnostic Kits
 Research Kits
o Assay Kits by Analyte
 T-cell-based kits
 B-cell-based kits
 Other analytic kits
• Analyzers
• Ancillary products
By Application-
• Diagnostic Applications
o Infectious Diseases
o Transplants
• Research Applications
o Vaccine Development
o Clinical Trials
o Cancer Research
By End-User-
• Hospitals & Clinical Labs
• Research Institutes
• Biopharmaceutical Companies and CROs
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

For More Customization @ https://www.insightaceanalytic.com/report/elispot-and-fluorospot-assay-market/2000

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.